Advate
Links shared publicly online about this topic
Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A
news-medical.net — “Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.” View full resource at news-medical.net
Most Recently Shared on July 26, 2011 at 1:46 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A... http://bit.ly/q90luz
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Oncology news and research via News-Medical.Net
Advertisement
